Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Novel Diagnostics and Therapies for Infectious Disease
share announcement

Novel Diagnostics and Therapies for Infectious Disease

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1679

Special Issue Editors

Dr. Mirela Loredana Grigoras

E-Mail Website
Guest Editor
Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: pathology; anatomy and embryology; pediatric infections; infection control; epidemiology; quality of life
Special Issues, Collections and Topics in MDPI journals
Dr. Felix Bratosin

E-Mail Website
Guest Editor
Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: gut microbiome; infectious diseases; antimicrobial resistance; respiratory infections; opportunistic infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are embarking on an exciting journey to explore the latest advancements in the field of infectious diseases, guided by our esteemed Guest Editors, Dr. Mirela Loredana Grigoras and Dr. Felix Bratosin. Their expertise spans across pathology, infection control, gut microbiome studies and antimicrobial resistance, offering a comprehensive view on contemporary challenges and solutions.

This Special Issue aims to bridge the gap between traditional methods and the latest innovations in diagnosing and treating infectious diseases, emphasizing the critical need for more effective and precise strategies in the current global health landscape.

Reflecting on the evolution of infectious disease management, this issue acknowledges past methodologies, while highlighting the importance of integrating new research and technology to combat emerging and re-emerging infections.

Our objective is to showcase research that pushes the boundaries of knowledge in infectious disease diagnostics and therapy, including, but not limited to, novel methodologies, technological advancements and comprehensive treatment strategies.

We invite papers that report on studies that offer insights into novel diagnostic tools, therapeutic approaches and their impacts on disease management, patient care and quality of life improvement.

We are looking for original research articles and review papers that contribute significantly to the fields of infectious diseases, particularly those that address challenges in diagnosing and treating complex infections, enhancing infection control and improving patient outcomes.

Dr. Mirela Loredana Grigoras
Dr. Felix Bratosin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • infectious diseases
  • diagnostic innovations
  • therapeutic advances
  • antimicrobial resistance
  • infection control
  • pediatric infections
  • gut microbiome
  • epidemiology
  • quality of life
  • opportunistic infections

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1074 KiB  
Article
Assessing the Utility of Prediction Scores PAINT, ISARIC4C, CHIS, and COVID-GRAM at Admission and Seven Days after Symptom Onset for COVID-19 Mortality
by Alina Doina Tanase, Oktrian FNU, Dan-Mihai Cristescu, Paula Irina Barata, Dana David, Emanuela-Lidia Petrescu, Daliana-Emanuela Bojoga, Teodora Hoinoiu and Alexandru Blidisel
J. Pers. Med. 2024, 14(9), 966; https://doi.org/10.3390/jpm14090966 - 11 Sep 2024
Viewed by 640
Abstract
The COVID-19 pandemic underscores the need for accurate prognostic tools to predict patient outcomes. This study evaluates the effectiveness of four prominent COVID-19 prediction scores—PAINT, ISARIC4C, CHIS, and COVID-GRAM—at two critical time points: at admission and seven days post-symptom onset, to assess their [...] Read more.
The COVID-19 pandemic underscores the need for accurate prognostic tools to predict patient outcomes. This study evaluates the effectiveness of four prominent COVID-19 prediction scores—PAINT, ISARIC4C, CHIS, and COVID-GRAM—at two critical time points: at admission and seven days post-symptom onset, to assess their utility in predicting mortality among hospitalized patients. Conducted at the Clinical Emergency Hospital Pius Brînzeu in Timișoara, this retrospective analysis included adult patients hospitalized with confirmed SARS-CoV-2 infection. Eligible patients had complete data for the scores at both time points. Statistical analysis involved ROC curves and logistic regression to assess the scores’ predictive accuracy for mortality. The study included 215 patients, split into 139 survivors and 76 non-survivors. At admission, the PAINT, ISARIC4C, CHIS, and COVID-GRAM scores significantly differentiated between the survival outcomes (p < 0.0001). The best cutoff values at admission were 6.26 for PAINT, 7.95 for ISARIC4C, 5.58 for CHIS, and 0.63 for COVID-GRAM, corresponding to sensitivities of 85.47%, 80.56%, 88.89%, and 83.33% and specificities of 77.34%, 82.12%, 75.01%, and 78.45%, respectively. By day seven, the cutoff values increased, indicating deteriorating conditions in patients who eventually succumbed to the virus. The hazard ratios at admission for exceeding these cutoffs were significant: PAINT (HR = 3.45), ISARIC4C (HR = 2.89), CHIS (HR = 4.02), and COVID-GRAM (HR = 3.15), highlighting the scores’ abilities to predict severe outcomes. One week post symptom onset, these scores’ predictive values and corresponding hazard ratios increased, further validating their prognostic significance over time. The evaluated COVID-19 prediction scores robustly predict mortality at admission and become more predictive by the seventh day of symptom onset. These findings support the use of these scores in clinical settings to facilitate early identification and intervention for high-risk patients, potentially improving patient outcomes during the ongoing global health crisis. Full article
(This article belongs to the Special Issue Novel Diagnostics and Therapies for Infectious Disease)
►▼ Show Figures

Figure 1

11 pages, 427 KiB  
Article
Evaluating the Utility of Clinical Scores APACHE, CURB, SOFA, and NEWS2 at Admission and 5-Days after Symptom Onset in Predicting Severe COVID-19 in Patients with Diabetes
by Radu Ion, Jaya Shankar Sai Kumar Kimidi, Chaitanya Kalapala, Oktrian FNU, Varshika Ramakrishnan Chandrababu, Omprakash Reddy Desireddygari, Mirela Loredana Grigras, Ovidiu Rosca, Felix Bratosin, Flavius Cioca, Romulus Timar and Rodica Anamaria Negrean
J. Pers. Med. 2024, 14(8), 868; https://doi.org/10.3390/jpm14080868 - 16 Aug 2024
Viewed by 725
Abstract
The elevated risk of severe COVID-19 outcomes in patients with diabetes underscores the need for effective predictive tools. This study aimed to assess the predictive accuracy of APACHE II, CURB-65, SOFA, and NEWS2 scores at critical time points in diabetic patients diagnosed with [...] Read more.
The elevated risk of severe COVID-19 outcomes in patients with diabetes underscores the need for effective predictive tools. This study aimed to assess the predictive accuracy of APACHE II, CURB-65, SOFA, and NEWS2 scores at critical time points in diabetic patients diagnosed with COVID-19, aiming to guide early and potentially life-saving interventions. In a prospective cohort study conducted from January 2021 to December 2023, adult patients with type 1 or type 2 diabetes and confirmed SARS-CoV-2 infection were evaluated. Clinical scores were calculated at admission and five days post-symptom onset, with data analyzed using receiver operating characteristic (ROC) curves and logistic regression to determine areas under the curve (AUC) and hazard ratios (HR) for severe outcomes. Among the 141 diabetic patients studied, ROC analysis revealed high AUC values for SOFA (0.771 at admission, 0.873 at day five) and NEWS2 (0.892 at admission, 0.729 at day five), indicating strong predictive accuracy for these scores. The APACHE II score’s AUC improved from 0.698 at admission to 0.806 on day five, reflecting worsening patient conditions. Regression analysis showed significant HRs associated with exceeding threshold scores: The SOFA score HR at day five was 3.07 (95% CI: 2.29–4.12, p < 0.001), indicating a threefold risk of severe outcomes. Similarly, the APACHE II score showed an HR of 2.96 (95% CI: 2.21–3.96, p < 0.001) at day five, highlighting its utility in predicting severe disease progression. The SOFA and NEWS2 scores demonstrated excellent early predictive accuracy for severe COVID-19 outcomes in diabetic patients, with significant AUC and HR findings. Continuous score monitoring, especially of APACHE II and SOFA, is crucial for managing and potentially mitigating severe complications in this vulnerable population. These tools can effectively assist in the timely escalation of care, thus potentially reducing morbidity and mortality among diabetic patients during the COVID-19 pandemic. Full article
(This article belongs to the Special Issue Novel Diagnostics and Therapies for Infectious Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop